Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations

BOSTON--(BUSINESS WIRE)--Apr. 26, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news